Neurocrine Biosciences (NBIX) Cash from Investing Activities Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.10 Bn | 625.34 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 441.68 Bn | 435.11 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 366.62 Bn | 359.48 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | -47.89% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 27.70% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 8 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | -91.04% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 33.61% |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | -2.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.45% |
| Mar 31, 2026 | -129.09% |
| Dec 31, 2025 | 22.94% |
| Sep 30, 2025 | -47.50% |
| Jun 30, 2025 | -42.99% |
| Mar 31, 2025 | 34.80% |
| Dec 31, 2024 | -69.64% |
| Sep 30, 2024 | 29.97% |
| Jun 30, 2024 | 32.28% |
| Mar 31, 2024 | -42.14% |
| Dec 31, 2023 | -10.96% |
| Sep 30, 2023 | -80.30% |
| Jun 30, 2023 | -49.60% |
| Mar 31, 2023 | -48.40% |
| Dec 31, 2022 | 11.40% |
| Sep 30, 2022 | 10.53% |
| Jun 30, 2022 | 374.25% |
| Mar 31, 2022 | -40.45% |
| Dec 31, 2021 | 30.51% |
| Sep 30, 2021 | -40.92% |